We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+39.37%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$191M
AUM Growth
+$41.4M
Cap. Flow
-$4.33M
Cap. Flow %
-2.27%
Top 10 Hldgs %
52.91%
Holding
54
New
5
Increased
14
Reduced
20
Closed
9

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$13.3M
2
LOXO
Loxo Oncology, Inc
LOXO
+$2.88M
3
PRTA icon
Prothena Corp
PRTA
+$2.68M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$1.96M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$1.47M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$2.97M
2
INDP icon
Indaptus Therapeutics
INDP
+$2.64M
3
AMAG
AMAG Pharmaceuticals
AMAG
+$2.62M
4
SUPN icon
Supernus Pharmaceuticals
SUPN
+$2.55M
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$2.06M

Sector Composition

Rank Sector Weight
1 Healthcare 92.98%
2 Miscellaneous 7.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTO
51
DELISTED
Altamira Therapeutics Ltd
CYTO
– –
-4
Closed -$1.43M
PRTK
52
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-146,700
Closed -$2.04M
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2016 Portfolio in Review

As of Q3 2016, Opaleye Management held 54 positions worth $191M, up 28% from $150M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Opaleye Management's Q3 2016 filing shows 5 new, 14 increased, 20 reduced and 9 closed positions. Its largest new stake was Loxo Oncology, Inc: 110,000 shares worth $2.88M. The largest sale was Amarin Corp, an estimated $2.97M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q3 2016 buy was Loxo Oncology, Inc: 110,000 shares worth $2.88M.
  • Opaleye Management added most to Blueprint Medicines in Q3 2016, an estimated $13.3M increase.
  • Opaleye Management's biggest Q3 2016 reduction was Amarin Corp, cutting an estimated $2.97M.
  • Opaleye Management fully exited Supernus Pharmaceuticals in Q3 2016, selling an estimated $2.55M.
  • Opaleye Management's ten largest holdings make up 53% of its $191M portfolio in Q3 2016.
  • Opaleye Management opened 5 new positions and closed 9 in Q3 2016.
  • Opaleye Management's portfolio value rose 28% quarter-over-quarter to $191M.

Based on Opaleye Management's 13F filing for Q3 2016, filed 14 Nov 2016.